A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle

Neurotoxicology and Teratology

Volumn 34, Issue 2, 2012, Pages 253-262

  Levi, Mark S ^a   Divine, Becky ^a   Hanig, Joseph P ^b   Doerge, Daniel R ^a   Vanlandingham, Michelle M ^a   George, Nysia I ^a   Twaddle, Nathan C ^a   Bowyer, John F ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amphetamines; Hyperthermia; Methamphetamine; Methylphenidate; Neurotoxicity; Waking cycle

Indexed keywords

AMPHETAMINE; DOPAMINE; METHAMPHETAMINE; METHYLPHENIDATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG BLOOD LEVEL; HYPERTHERMIA; LETHALITY; MALE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SLEEP PATTERN; THALAMUS; WAKEFULNESS;

AMPHETAMINES; ANIMALS; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; DOPAMINE; FEVER; MALE; METHAMPHETAMINE; METHYLPHENIDATE; PHOTOPERIOD; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

ANIMALIA; RATTUS; RODENTIA;

EID: 84856799856     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2012.01.007     Document Type: Article

References (62)

1. Bowyer J.F., Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006, 60:521-532.
2. Bowyer J.F., Holson R.R. Methamphetamine and amphetamine neurotoxicity: characteristics, interactions with body temperature and possible mechanisms. Handbook of Neurotoxicology 1995, 845-870. Marcel Dekker Inc., New York. L.W. Chang, R.S. Dyer (Eds.).
3. Bowyer J.F., Tank A.W., Newport G.D., Slikker W., Ali S.F., Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 1992, 260:817-824.
4. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994, 268:1571-1580.
5. Bowyer J.F., Peterson S.L., Rountree R.L., Tor-Agbidye J., Wang G.J. Neuronal degeneration in rat forebrain resulting from D-amphetamine-induced convulsions is dependent on seizure severity and age. Brain Res 1998, 809:77-90.
6. Bowyer J.F., Delongchamp R.R., Jakab R.L. Glutamate N-methyl-D-aspartate and dopamine receptors have contrasting effects on the limbic versus the somatosensory cortex with respect to amphetamine-induced neurodegeneration. Brain Res 2004, 1030:234-246.
7. Bowyer J.F., Thomas M.T., Schmued L.C., Ali S.F. Brain region-specific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures and the blood-brain barrier. Ann NY Acad Sci 2008, 1139:127-139.
8. Briese E. Normal body temperature of rats: the setpoint controversy. Neurosci Biobehav Rev 1998, 22:427-436.
9. Broening H.W., Pu C., Vorhees C.V. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 1997, 27:153-160.
10. Cho A.K., Melega W.P., Kuczenski R., Segal D.S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001, 39:161-166.
11. Clausing P., Gough B., Holson R.R., Slikker W., Bowyer J.F. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. J Pharmacol Exp Ther 1995, 274:614-621.
12. Deng X., Wang Y., Chou J., Cadet J.L. Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res Mol Brain Res 2001, 93:64-69.
13. Eisch A.J., Schmued L.C., Marshall J.F. Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine. Synapse 1998, 30:329-333.
14. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 1978, 201:276-278.
15. Faraone S.V. Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release). Expert Opin Pharmacother 2007, 8:2127-2134.
16. Fenichel R.R. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 1995, 5:155-156.
17. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
18. Goodman D.W. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract 2007, 13:318-327.
19. Hutchaleelaha A., Sukbuntherng J., Chow H.H., Mayersohn M. Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metab Dispos 1994, 22:406-411.
20. Hutchaleelaha A., Walters A., Chow H.H., Mayersohn M. Sensitive enantiomer-specific high-performance liquid chromatographic analysis of methamphetamine and amphetamine from serum using precolumn fluorescent derivatization. J Chromatogr B Biomed Appl 1994, 658:103-112.
21. Inoue H., Ikeda N., Kudo K., Ishida T., Terada M., Matoba R. Methamphetamine-related sudden death with a concentration which was of a 'toxic level'. Leg Med 2006, 8:150-155.
22. Ishigami A., Tokunaga I., Gotohda T., Kubo S. Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers. Leg Med (Tokyo) 2003, 5:42-48.
23. Kalant H., Kalant O.J. Death in amphetamine users: causes and rates. Can Med Assoc J 1975, 112:299-304.
24. Kalasinsky K.S., Bosy T.Z., Schmunk G.A., Reiber G., Anthony R.M., Furukawa Y., et al. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 2001, 116:163-169.
25. Kantak K.M., Singh T., Kerstetter K.A., Dembro K.A., Mutebi M.M., Harvey R.C., et al. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci 2008, 122:340-357.
26. Koda L.Y., Gibb J.W. Adrenal and striatal tyrosine hydroxylase activity after methamphetamine. J Pharmacol Exp Ther 1973, 185:42-48.
27. Lewander T. Urinary excretion and tissue levels of catecholamines during chronic amphetamine intoxication. Psychopharmacologia 1968, 13:394-407.
28. Lopez F.A. ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr 2006, 27:410-416.
29. Manjanatha M.G., Shelton S.D., Dobrovolsky V.N., Shaddock J.G., McGarrity L.G., Danie R.D., et al. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. Environ Mol Mutagen 2008, 49:585-593.
30. Maxim P. Methylphenidate. Clin Toxicol Rev 2000, 22.
31. McGee S.M., McGee D.N., McGee M.B. Spontaneous intracerebral hemorrhage related to methamphetamine abuse: autopsy findings and clinical correlation. Am J Forensic Med Pathol 2004, 25:334-337.
32. Miller M.A., Coon T.P. Re: delayed ischemic stroke associated with methamphetamine use. J Emerg Med 2006, 31:305-306. author reply 6.
33. Miller D.B., O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994, 270:752-760.
34. Morton W.A., Stockton G.G. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry 2000, 2:159-164.
35. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994, 270:741-751.
36. O'Callaghan J.P., Miller D.B. Neurotoxic effects of substituted amphetamines in rats and mice. Handbook of Neurotoxicology 2001, 269-301. Humana Press Inc., Totowa, NJ. E.J. Massaro (Ed.).
37. Parasrampuria D.A., Schoedel K.A., Schuller R., Gu J., Ciccone P., Silber S.A., et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007, 47:1476-1488.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1995, Academic Press, San Diego, CA.
39. Quinton M.S., Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006, 8:E337-E347.
40. Redalieu E., Bartlett M.F., Waldes L.M., Darrow W.R., Egger H., Wagner W.E. A study of methylphenidate in man with respect to its major metabolite. Drug Metab Dispos 1982, 10:708-709.
41. Richards J.R., Johnson E.B., Stark R.W., Derlet R.W. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 1999, 17:681-685.
42. Ropper A.H., Samuels M.A. Adams and Victor's Principles of Neurology 2009, McGraw-Hill, New York.
43. Rothrock J.F., Rubenstein R., Lyden P.D. Ischemic stroke associated with methamphetamine inhalation. Neurology 1988, 38:589-592.
44. Scharman E.J., Erdman A.R., Cobaugh D.J., Olson K.R., Woolf A.D., Caravati E.M., et al. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management*. Clin Toxicol 2007, 45:737-752.
45. Schmued L.C., Bowyer J.F. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res 1997, 759:135-140.
46. Schmued L.C., Stowers C.C., Scallet A.C., Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005, 1035:24-31.
47. Seiden L.S., Sabol K.E. Neurotoxicity of methamphetamine-related drugs and cocaine. Handbook of Neurotoxicology 1995, 824-844. Marcel Dekker Inc., New York, Basel, Hong Kong. L. Chang (Ed.).
48. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1976, 1:215-219.
49. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993, 33:639-677.
50. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 1994, 17:203-209.
51. Streit W.J. An improved staining method for rat microglial cells using the lectin from Griffonia simplicifolia (GSA I-B4). J Histochem Cytochem 1990, 38:1683-1686.
52. Swanson J.M., Volkow N.D. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 2002, 130:73-78.
53. Team RDC R: a language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna, Austria. 2.7.2 ed.
54. Tokunaga I., Kubo S., Ishigami A., Gotohda T., Kitamura O. Changes in renal function and oxidative damage in methamphetamine-treated rat. Leg Med (Tokyo) 2006, 8:16-21.
55. Twaddle N.C., Vanlandingham M.M., Levi M.S., Bowyer J.F., Williams L.D., Doerge D.R. UPLC-ES/MS/MS Analysis of Amphetamine, Methamphetamine and Methylphenidate in Rat Serum using Supported Liquid Extraction 2011, American Society for Mass Spectrometry.
56. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Franceschi D., Maynard L., et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002, 43:181-187.
57. Wargin W., Patrick K., Kilts C., Gualtieri C.T., Ellington K., Mueller R.A., et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983, 226:382-386.
58. Wigal S.B., Gupta S., Greenhill L., Posner K., Lerner M., Steinhoff K., et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007, 17:153-164.
59. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996, 2:699-703.
60. Wilson J.M., Levey A.I., Bergeron C., Kalasinsky K., Ang L., Peretti F., et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996, 40:428-439.
61. Winslow B.T., Voorhees K.I., Pehl K.A. Methamphetamine abuse. Am Fam Physician 2007, 76:1169-1174.
62. Wultz B., Sagvolden T., Moser E.I., Moser M.B. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behav Neural Biol 1990, 53:88-102.